In this article, we will discuss Tazemetostat (Dosage Overview). So, let’s get started.
Tazemetostat is indicated for the treatment of adults and pediatric patients aged 16 years and older with metastatic or locally advanced epithelioid sarcoma not eligible for complete resection. This indication is approved under accelerated approval based on overall response rate and duration of response.
Relapsed or Refractory Follicular Lymphoma
- Tazemetostat is indicated for the treatment of adult patients with relapsed or refractory (R/R) follicular lymphoma (FL) whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies.
- Tazemetostat is indicated for the treatment of adult patients with R/R FL who have no satisfactory alternative treatment options. These indications are approved under accelerated approval based on overall response rate and duration of response.
Select patients with R/R FL for treatment with TAZVERIK based on the presence of EZH2 mutation of codons Y646, A682, or A692 in tumor specimens.
The recommended dosage of Tazemetostat is 800 mg orally twice daily with or without food until disease progression or unacceptable toxicity.